Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imipramine SCHEMBL34282 | 1.00 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL17004048 | 1.00 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL6118138 | 1.00 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL41766 | 0.98 | LMNA (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL29040915 | 0.98 | SLC6A4 (0.97) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL41765 | 0.98 | LMNA (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL28759733 | 0.98 | LMNA (1.00) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL27657924 | 0.98 | SLC6A4 (0.97) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL15719828 | 0.97 | LMNA (0.97) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 | |
| Imipramine SCHEMBL3002670 | 0.97 | SLC6A4 (0.94) | SLC6A4HRH1HTR2ACYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| EP-3625238-B1 | NOVEL SPIRO-LACTAM COMPOUNDS, PROCESS AND USES THEREOF | UNIV DE COIMBRA (PT) | 2025-11-26 | — | — | EP | claimed |
| EP-3823328-B1 | METHOD AND DEVICE FOR DOWNLOADING PROFILE IN MOBILE COMMUNICATION SYSTEM | SAMSUNG ELECTRONICS CO LTD (KR) | 2025-10-29 | — | — | EP | claimed |
| WO-2025206418-A1 | SINK DEVICE AND OPERATION METHOD THEREOF | 엘지전자 주식회사 | 2025-10-02 | — | — | WO | claimed |
| US-12368324-B2 | Inductive coupling system and method for adaptive control of power transfer for wireless three-dimensional stacked chip package | ZHEJIANG UNIVERSITY (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2025-07-10 | — | — | US | claimed |
| EP-4208466-B1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2025-06-11 | — | — | EP | claimed |
| CN-120022401-A | Intelligent monitoring and quality control system of sterilizer | 贵州中医药大学第一附属医院 | 2025-05-23 | — | — | CN | claimed |
| CN-110365553-B | IPv6 network flow monitoring method and system based on SDN | 湘潭大学 | 2022-11-22 | — | — | CN | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| CN-114755348-B | Method for simultaneously detecting contents of 20 medicines and metabolites thereof | 北京和合医学诊断技术股份有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114755348-A | Method for simultaneously detecting contents of 20 medicines and metabolites thereof | 北京和合医学诊断技术股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-110481308-B | Comprehensive cooling control method for driving motor of new energy vehicle | 重庆长安汽车股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| EP-3753966-B1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | SHANGHAI BEST LINK BIOSCIENCE LLC (CN) | 2022-05-25 | — | — | EP | claimed |
| EP-3454853-B1 | TREATMENT OF ALCOHOLISM AND DEPRESSION USING IBUDILAST | MEDICINOVA INC (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114448984-A | Adaptive method of cross-platform general SDN controller | 国家电网有限公司信息通信分公司 | 2022-05-06 | — | — | CN | claimed |
| CN-114189354-A | SYN Flooding network attack scene reproduction method | 西安理工大学 | 2022-03-15 | — | — | CN | claimed |
| CN-109150604-B | SDN-based power communication network system and cross-domain slicing method | 南瑞集团有限公司 | 2022-01-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | NOX4, NOX1, NOX3 | SLC6A4 4878/4885SLC6A2 4795/4885HRH1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.